1. SARS-CoV-2 serologic surveillance among people living with HIV in Nigeria, April 2022 to January 2023
- Author
-
Helen M. Chun, Sophia Osawe, Samuel Adams-Dabban, Jennifer Favaloro, Nnaemeka C. Iriemenam, Emilio Dirlikov, Diana Martin, Kyle Milligan, Andrew Abutu, Olumide Okunoye, Mary Okoli, Olusola Akanbi, Oluwaseun Akinmulero, Rita Okonkwo, Oyewole Oyedele, Stacie Greby, Alash'le Abimiku, McPaul I.J. Okoye, Ray W. Shiraishi, Dickson Adegoke, Mustapha Bello, Felix Villeng, Item Inya Item, Simon Gabo, Ado Abubakar, Andrew Thomas, Temitope Olaleye, Samuel Awala, Felicia Nwatu, Blessing Ugboaja, Ifeanyi Udoh, Loveth Akayi, Joseph Dattijo, Tolulope Adenekan, Asmau Aminu-Alhaji, and Ijeoma Ezeuko
- Subjects
SARS-CoV-2 ,PLHIV ,COVID-19 ,Infectious and parasitic diseases ,RC109-216 - Abstract
Objectives: Evidence indicates that people living with HIV (PLHIV) are more impacted by COVID-19. The burden of SARS-CoV-2 infection among PLHIV is unknown in Nigeria. Methods: We conducted repeated cross-sectional SARS-CoV-2 serosurveys in 14 states and the Federal Capital Territory in Nigeria among PLHIV who had an HIV viral load (VL) test during April 2022 to January 2023. Evidence of SARS-CoV-2 immunoglobulin G (IgG) antibodies was assessed using a multiplex bead assay to measure IgG to spike (S), receptor binding domain (RBD), and nucleocapsid (N) proteins to identify potential infection and/or vaccination status. Results: Between April 2022 and January 2023, 47,614 remnant VL samples were included and tested for SARS-CoV-2 antibodies. Seroprevalence of SARS-CoV-2 infection, defined as IgG antibodies to spike and RBD591 [S+] and nucleocapsid [N+], (S+N+), ranged between 21.1% (95% confidence intervals [CI]: 11.4-31.8) in Ekiti State in January 2023 to 71.4% (95% CI 71.9-81.9) in Gombe State in November 2022, with overall steady trends within and between states over time, across age and sex. Conclusion: High rates of SARS-CoV-2 antibody seroprevalence among PLHIV in Nigeria were observed. This underscores the need to understand the association between HIV and SARS-CoV-2 to inform strategies to reduce the threat posed by COVID-19.
- Published
- 2025
- Full Text
- View/download PDF